Exelixis

Youtube Subscribe

Open: 19.91 Close: 19.86 Change: -0.05

The best way to get informed about Exelixis Company Inc without reading hundreds of pages.

The game is changing. There is a new strategy to evaluate Exelixis fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Exelixis are: Exelixis, price, stock, Inc, last, increase, patent, and the …

Concept Map

Semantic Network

Stock Summary

Exelixis, Inc. focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell.

Today's Summary

Exelixis stock was originally listed at a price of $14.75 in 2000. Morgan Stanley dropped their price target on ExelIXis from $22.00 to $21.00.

Today's News

Exelixis Inc. to be replaced by exelixixis, Inc. in the U.S. marketwatch.com. Exelixis (NASDAQ:EXEL – Get Rating ) last released its quarterly earnings data on Tuesday, May 9th. Morgan Stanley dropped their price target on ExelIXis from $22.00 to $21.00 and set an “equal weight” rating for the company in a research note on April 12th. Stifel Nicolaus increased their price objective on shares of Exelsceptil F Chun Sisters Haipple Combways exchlloipop criminality Exelixis stock was originally listed at a price of $14.75 in 2000. If you had invested in Exelis stock at $19.75, your last 23 years would have been 34.3%. Exelixis and MSN are about to go to trial over Cabometyx. Googles policy statement on patent reform reiterates desire that patents should be worthless. Exelixis is hiring Senior Director and Patents Counsel (Small Molecules) in King of Prussia, Pennsylvania. As at Jun 23, 2023, the EXEL stock has a PE ratio of 41.38. Cervical Cancer Market Size is Likely to Increase, Examines DelveInsight | Key Companies in the Market - Gilead, Roche, Genentech, Iovance, Bristol-Myers Squibb, Exelixis, Xencor, Merck, EMD Serono, Fusion, AstraZeneca. Cervicals cancer market is expected to increase, due to factors that encourage screening disclose ther troubles67EMBER Psycho wait constitu Dewapolis arous deteriorated

Stock Profile

"Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human monoclonal antibody against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California."

Keywords

Are looking for the most relevant information about Exelixis? Investor spend a lot of time searching for information to make investment decisions in Exelixis. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Exelixis are: Exelixis, price, stock, Inc, last, increase, patent, and the most common words in the summary are: exelixis, therapeutic, stock, exel, pharmaceutical, inc, forecast, . One of the sentences in the summary was: Exelixis stock was originally listed at a price of $14.75 in 2000. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #exelixis #therapeutic #stock #exel #pharmaceutical #inc #forecast.

Read more →

Youtube Subscribe

---